Avant Brands Past Earnings Performance
Past criteria checks 0/6
Avant Brands has been growing earnings at an average annual rate of 4.7%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 44.6% per year.
Key information
4.7%
Earnings growth rate
25.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 44.6% |
| Return on equity | -24.5% |
| Net Margin | -40.7% |
| Last Earnings Update | 31 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Avant Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 May 24 | 28 | -11 | 12 | 0 |
| 29 Feb 24 | 27 | -8 | 11 | 0 |
| 30 Nov 23 | 26 | -5 | 12 | 0 |
| 31 Aug 23 | 29 | -4 | 11 | 0 |
| 31 May 23 | 27 | -3 | 9 | 0 |
| 28 Feb 23 | 23 | -7 | 12 | 0 |
| 30 Nov 22 | 20 | -8 | 11 | 0 |
| 31 Aug 22 | 15 | -10 | 11 | 0 |
| 31 May 22 | 13 | -14 | 10 | 0 |
| 28 Feb 22 | 12 | -12 | 7 | 0 |
| 30 Nov 21 | 9 | -11 | 6 | 0 |
| 31 Aug 21 | 9 | -11 | 5 | 0 |
| 31 May 21 | 9 | -9 | 5 | 0 |
| 28 Feb 21 | 8 | -8 | 5 | 0 |
| 30 Nov 20 | 8 | -10 | 5 | 0 |
| 31 Aug 20 | 7 | -4 | 5 | 0 |
| 31 May 20 | 6 | -6 | 6 | 0 |
| 29 Feb 20 | 5 | -8 | 7 | 0 |
| 30 Nov 19 | 2 | -10 | 9 | 0 |
| 31 Aug 19 | 1 | -11 | 10 | 0 |
| 31 May 19 | 0 | -11 | 11 | 0 |
| 28 Feb 19 | 0 | -10 | 10 | 0 |
| 30 Nov 18 | 0 | -11 | 10 | 0 |
Quality Earnings: 1BU is currently unprofitable.
Growing Profit Margin: 1BU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1BU is unprofitable, but has reduced losses over the past 5 years at a rate of 4.7% per year.
Accelerating Growth: Unable to compare 1BU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1BU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: 1BU has a negative Return on Equity (-24.48%), as it is currently unprofitable.